Devyser Diagnostics AB (publ) (DVYSR) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Devizor Q1 2026 earnings call. My name is Jan Wallström, I'm the CEO of Devizor and would like to thank you everyone for joining our call today. On the call today we have in addition to myself also our CFO Sabina Berlin. I will start with a short summary of highlights from the quarter before handing over to Sabina for a more detailed review of our financial results for January to March. And then we'll go through an update on our recent commercial activities. First quarter came in with a positive EBIT, the fourth consecutive quarter in a row. As you know, we started the journey in the beginning of last year, focusing on the company towards profitable growth. It's been a successful journey and we're happy to deliver a strong growth and positive EBIT. In the first quarter of the year, we continue to grow faster than the market. We grew 24% in fixed currencies. We received quite a few orders from Thermo in this quarter, a step towards a more stable order pattern. We're also very pleased with the gross margin of 82%. It's better than full year 2025, and we will continue to work on improving cost of goods sold. EBIT came in on a positive 2.6 million compared to last year's negative 14.8 in the first quarter. So we're growing faster than the market with a clear focus on profitable growth. In the first quarter, we signed the agreement to acquire CyberGene, a Swedish company with products in similar areas as Devizor, giving us a stronger commercial position in several markets. Cybergene is a Stockholm-based agnostic company and has operated in the same market as Devizor for many years providing Devizor with in-depth knowledge of Cybergene's products and customers. The acquisition was completed on April 1st and we have already integrated the com...